drugset / Trial / NCT03492268

Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma

NCT03492268

NaSingle-groupOpen-labelTreatment

Summary

This trial aims to evaluate the safety and efficacy of BCMA-CART in treating patients with relapsed or refractory multiple myeloma.

Timeline

Start
2021-11-01
Primary completion
2022-12
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject BCMA CAR-T Cell therapy

Indications